ApicHope Pharmaceutical Group (300723.SZ) obtained the registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution.

ApicHope Pharmaceutical Group (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Group Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution approved and issued by the National Medical Products Administration. The receipt of the registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution marks that the company is qualified to sell this specification of the drug in the domestic market. This will further enrich the company's product pipeline and product categories, and enhance the company's competitiveness in chronic disease drugs.